Myovant Sciences Ltd Stock News

Relugolix is approved and launched in two indications and could establish itself as a new Standard of Care. The inked 4.2 billion deal with top-class partner Pfizer verifies the blockbuster potential

Myovant Sciences (MYOV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Tucked in its Q2 earnings release, Myovant Sciences Ltd (NYSE: MYOV) said that Pfizer Inc (NYSE: PFE) has notified its option decision for international rights to relugolix in oncology. Pfizer dec

Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q2 2021 Results - Earnings Call Transcript

BASEL, Switzerland and NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced the presentation of new data from clinical studies of its

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Announces Leadership Appointments to Drive Future Growth and Geographic Expansion

BASEL, Switzerland, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and

RETHYMIC is the first and only FDA-approved treatment indicated for immune reconstitution in pediatric patients with congenital athymia

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Presents Data for GEMTESA® (vibegron) 75 mg in Overactive Bladder Showing No Significant Effects on Blood Pressure or Heart Rate

Myovant's (MYOV) application for the label expansion of Myfembree gets accepted by the FDA for the indication of pain associated with endometriosis.

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Present New Data at the Virtual 2021 Annual Meeting of the American Urological Association

BASEL, Switzerland, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the 2021 Baird Global

Second-quarter earnings results were a little bit disappointing.

Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q1 2021 Results - Earnings Call Transcript